Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics

  • Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights, and will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications
  • NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using its proprietary MATCH™ technology platform
  • Novo Holdings co-led Numab’s $110 million Series C financing in 2021 and participated in the Series C extension in 2022
  • Michael Bauer, Partner, Venture Investments, Novo Holdings continues on the Board of Numab Therapeutics AG

Read more…